Jonathan Alspaugh - 09 Dec 2021 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (AGLE)

Role: Chief Financial Officer
Signature: /s/ Steven Weber, by power of attorney
Issuer symbol: AGLE
Transactions as of: 09 Dec 2021
Net transactions value: +$186,000
Form type: 4
Filing time: 13 Dec 2021, 19:37:40 UTC
Previous filing: 18 Aug 2021
Next filing: 22 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AGLE	Common Stock	Purchase	$186,000	+50,000	+124%	$3.72^*	90,372	09 Dec 2021	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.64 to $3.94 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

Content

The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.64 to $3.94 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth herein.